Human growth hormone patch formulations
US7947304B2 · kind B2 · utility
1Cited by
10References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2006 |
| Grant date | May 24, 2011 |
| Priority date | — |
| Expiry date | Nov 2, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.